Skip to main content

Skye Bioscience, Inc.

Data quality: 83%
SKYE
Nasdaq Manufacturing Chemicals
$0.73
▲ $0.02 (2.52%)
Mkt Cap: 24.20 M
Price
$0.73
Mkt Cap
24.20 M
Day Range
$0.69 — $0.73
52-Week Range
$0.57 — $5.75
Volume
68,449
Open $0.70
50D / 200D Avg
$0.76
4.59% below
50D / 200D Avg
$2.07
64.97% below

Quick Summary

Key Takeaways

Negative free cash flow of -43.07 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-146.18%
Below sector avg (-53.41%)
ROIC-119.65%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio4.77
Interest CoverageN/A

Valuation

PE (TTM)
-0.43
Above sector avg (-1.48)
P/B Ratio0.74
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -0.4 -1.5
P/B 0.7 1.6
ROE % -146.2 -53.4
Net Margin % -41.5
Rev Growth 5Y % 1.8
D/E 0.3

ETFs Holding This Stock

BRSIX BRSIX
0.07% weight

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -55.92 M
ROE -146.18% ROA -119.64%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -43.07 M
ROIC -119.65% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4.77
Interest Coverage N/A Asset Turnover N/A
Working Capital 31.56 M Tangible Book Value 32.84 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.43 Forward P/E N/A
P/B Ratio 0.74 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -177.97%
Market Cap 24.20 M Enterprise Value 5.76 M
Per Share
EPS (Diluted TTM) -1.41 Revenue / Share N/A
FCF / Share -1.29 OCF / Share -1.29
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 77.01%
SBC-Adj. FCF -51.14 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue
Net Income -55.92 M -26.57 M -37.64 M -19.48 M -8.52 M
EPS (Diluted) -1.41 -0.73 -5.37 -0.04 -0.02
Gross Profit
Operating Income -58.16 M -30.19 M -34.74 M -18.31 M -7.85 M
EBITDA
R&D Expenses 6.01 M 2.93 M
SG&A Expenses
D&A 723,352.0 298,640.0
Interest Expense 0.0 749,308.0 906,270.0 665,133.0 769,159.0
Income Tax 5,400.0 10,071.0 3,600.0 6,741.0 2,100.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 28.31 M 72.76 M 11.94 M 9.11 M 9.86 M
Total Liabilities 8.29 M 4.61 M 14.07 M 12.12 M 3.99 M
Shareholders' Equity 20.02 M 68.15 M -2.13 M -3.01 M 5.86 M
Total Debt
Cash & Equivalents 5.88 M 68.42 M
Current Assets 27.09 M 70.83 M 11.65 M 8.94 M 9.61 M
Current Liabilities 8.21 M 4.34 M 13.90 M 12.12 M 3.91 M